Observational Study of Pharmacological Treatment for Premature Ejaculation Concurrent With Erectile Dysfunction

Phase 3

• Conditions: Premature Ejaculation; Erectile Dysfunction
• Interventions: Drug: Dapoxetine; Drug: Tadalafil

• Registration Number: NCT04361305
• Lead Sponsor: Yan-Ping Huang

Brief Summary

Premature ejaculation (PE) is a common disease in the andrology clinic. Currently, the effectiveness and outcome differences of drug treatment still need to be studied and demonstrated. Premature ejaculation concurrent with erectile dysfunction (ED) is common in outpatient clinics. The preferred treatment plan for these patients still needs to be further studied and explored, and the difference in the efficacy of different treatment regiments remain to be evaluated.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-04
• Study First Submitted: 2020-04-22
• Study First Submitted QC: 2020-04-23
• Last Update Submitted: 2020-04-23
• Study First Posted: 2020-04-24
• Last Update Posted: 2020-04-24
• Study Start: 2020-06-03
• Primary Completion: 2021-01-11
• Study Completion: 2021-04-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 150

Inclusion Criteria

1. PE concurrent with ED: the IELT is less than 3 minutes, the PEDT score is ≥11 points, and 5≤IIEF-5≤21 points.
2. 18-60 years old, outpatient or physical examination population, with regular sex partners and regular sex life;
3. Having the data below,and willing to participate in the trial（1）Demographic information: age, gender, nationality, birthplace, etc;(2) Physical examination data: height, weight, abdominal circumference, blood pressure, heart rate, etc ;(3) Medical history data: history of present illness, past medical history, family history, etc;(4) Scale evaluation: Premature Ejaculation Diagnostic Tool (PEDT), Premature Ejaculation Profile (PEP), International Erectile Function Score-5(IIEF-5), Erectile Hardness Grading Score (EHGS), Clinical Global Impression of Change (GICC);

Exclusion Criteria

1. Age <18 years or> 60 years;
2. There is a history of acute and chronic diseases, major trauma and surgery, etc;
3. A long history of medication;
4. There is a history of unstable myocardial infarction and cerebral infarction;
5. A history of cardiogenic shock, severe heart failure, severe ventricular arrhythmia, etc;
6. There are serious diseases such as malignant tumors, chronic liver and kidney diseases, etc.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
tadalafil combined with dapoxetine	Dapoxetine	-
tadalafil combined with dapoxetine	Tadalafil	-
tadalafil mono group	Tadalafil	-

Primary Outcome Measures

Name	Time	Method
The change of Premature Ejaculation Profile (PEP) at week 8	Baseline, Week 8	The PEP is a 4-question PRO that asks a respondent about his subjective sense of control over ejaculation, distress related to PE, interpersonal difficulty and satisfaction with sexual intercourse.
The change of International Index of Erectile Function -5(IIEF-5) at week 8	Baseline, Week 8

Secondary Outcome Measures

Name	Time	Method
Incidence of adverse reactions	Baseline, Week 8	To observe the safety of the two regiments in PE concurrent with ED patients
The change of Erection Hardness Score (EHS)	Baseline, Week 8	Erection Hardness Score as a self-reporting measure that scored erection hardness on a 4 point scale. The aim was to help men, their partners and doctors diagnose erectile dysfunction.
Clinical Global Impression of Change (GICC)	Baseline, Week 8	Clinical Global Impression is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.